BTAIBioXcel Therapeutics Inc
$1.17
$0.03
(2.70%)
Closed $1.14
$0.0297
(2.60%)
After Hours
Reported EarningsMay 15
Mkt Cap$34.27M
Vol491,244.00
Fundamentals
Mkt Cap
$34.27M
Volume
-
52W High
$8.08
52W Low
$1.01
PE Ratio
-0.18
Avg. Volume
705,094.25
EPS (Annual)
-$5.73
Rev/Employee
$22,137.93
Earnings
May 15
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, April 9, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...
PR Newswire
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.read more...
Benzinga
Defense, Biotech, and Aerospace Stories Dominate
Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing. $KBLB, $IBO, $GXAI, $MOBX, $BTAI, $ALTO
24-7 Market News
BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval...
Nasdaq News: Markets
<
1
2
...
>